Ocugen Reports Q2 2025 Financial Results and Provides Business Update, Initiates Dosing in OCU410ST Phase 2/3 GARDian3 Pivotal Trial and Advances OCU400 Phase 3 liMeliGhT Clinical Trial.

Ocugen reported Q2 2025 financial results, highlighting the initiation of dosing in OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clinical trial, active dosing in OCU400 Phase 3 liMeliGhT clinical trial, and a proposed reverse merger with OrthoCellix to unlock NeoCart/regenerative cell therapies. The company also signed a binding term sheet for exclusive Korean rights to OCU400 with upfront fees and near-term development milestone payments totaling up to $11 million.